v3.26.1
Condensed Consolidated Balance Sheets (Unaudited) - USD ($)
$ in Millions
Jun. 30, 2026
Dec. 31, 2025
Current assets:    
Cash and cash equivalents $ 1,285.0 $ 3,008.5
Current portion of marketable securities 0.0 807.2
Inventory 2,384.3 2,168.1
Other current assets 1,238.0 1,123.3
Total current assets 7,305.7 8,974.1
Marketable securities 0.0 431.9
Property, plant and equipment, net 2,994.1 3,055.4
Operating lease assets 245.7 265.4
Intangible assets, net 13,516.4 9,178.5
Goodwill 6,990.8 6,491.1
Deferred tax asset 202.1 292.5
Investments and other assets 831.8 750.6
Total assets 32,086.6 29,439.5
Current liabilities:    
Current portion of term loan 800.0 0.0
Taxes payable 86.9 114.8
Accounts payable 403.9 432.0
Accrued expense and other 2,626.3 2,802.6
Total current liabilities 3,917.1 3,349.4
Notes payable and term loan 7,290.3 6,286.8
Deferred tax liability 945.5 507.6
Long-term operating lease liabilities 264.8 290.4
Other long-term liabilities 820.9 748.5
Total liabilities 13,238.6 11,182.7
Commitments, contingencies and guarantees
Biogen Inc. shareholders’ equity:    
Preferred stock, par value $0.001 per share 0.0 0.0
Common stock, par value $0.0005 per share 0.1 0.1
Additional paid-in capital 983.0 863.1
Accumulated other comprehensive income (loss) (127.7) (182.0)
Retained earnings 20,969.7 20,552.7
Treasury stock, at cost (2,977.1) (2,977.1)
Total equity 18,848.0 18,256.8
Total liabilities and equity 32,086.6 29,439.5
Nonrelated Party    
Current assets:    
Accounts receivable, net of allowance for doubtful accounts of $2.9 and $3.0, respectively 1,885.6 1,342.4
Related Party    
Current assets:    
Accounts receivable, net of allowance for doubtful accounts of $2.9 and $3.0, respectively $ 512.8 $ 524.6